Lakefront Biotherapeutics (LKFT) Operating Leases (2019 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Operating Leases of $5.7 million for Q1 2026, down 30.66% year-over-year from $8.2 million in Q1 2025, and down 5.92% quarter-over-quarter from $6.0 million in Q4 2025.
Lakefront Biotherapeutics (LKFT) Operating Leases (2019 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Operating Leases for 8 consecutive years, with $5.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 30.66% year-over-year to $5.7 million; the TTM figure through Mar 2026 stood at $5.7 million (down 30.66% YoY), while the FY2025 annual figure was $6.0 million, down 51.81% from the prior year.
- Operating Leases eased to $5.7 million in Q1 2026 per LKFT's latest filing, from $6.0 million in the prior quarter.
- Across five years, Operating Leases topped out at $20.5 million in Q1 2022 and bottomed at $4.2 million in Q1 2024.
- Historically, Operating Leases has averaged $9.6 million across 5 years, with a median of $8.2 million in 2025.
- Annual changes were most pronounced in 2024 — Operating Leases tumbled 61.99% — and 2025, when it soared 96.5%.
- Lakefront Biotherapeutics' Operating Leases stood at $15.0 million in 2022, then plunged by 31.12% to $10.3 million in 2023, then rose by 21.32% to $12.5 million in 2024, then plunged by 51.81% to $6.0 million in 2025, then slipped by 5.92% to $5.7 million in 2026.
- Business Quant data shows LKFT's Operating Leases at $5.7 million in Q1 2026, $6.0 million in Q4 2025, and $6.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.68 Mn |
| Dec 31, 2025 | 6.04 Mn |
| Sep 30, 2025 | 6.74 Mn |
| Jun 30, 2025 | 6.85 Mn |
| Mar 31, 2025 | 8.19 Mn |
| Dec 31, 2024 | 12.53 Mn |
| Sep 30, 2024 | 7.95 Mn |
| Mar 31, 2024 | 4.17 Mn |
| Dec 31, 2023 | 10.32 Mn |
| Sep 30, 2023 | 9.22 Mn |
| Mar 31, 2023 | 10.97 Mn |
| Dec 31, 2022 | 14.99 Mn |
| Mar 31, 2022 | 20.53 Mn |
| Dec 31, 2021 | 22.48 Mn |
| Jun 30, 2021 | 25.81 Mn |
| Dec 31, 2020 | 27.46 Mn |
| Jun 30, 2020 | 22.45 Mn |
| Mar 31, 2020 | 20.82 Mn |
| Dec 31, 2019 | 21.65 Mn |
| Sep 30, 2019 | 21.88 Mn |